Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients

Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients

Abstract Background Among breast cancer (BC) patients, near 40% are post-menopause, and 70%–80% are hormone receptor (HR)-positive. About 30%–40% BC patients who are diagnosed as invasive carcinoma HR-positive BC would eventually develop metastatic breast cancers. In 2016, FALCON trial proves Fulves...

Full description

Bibliographic Details
Main Authors: Jingyu Liu, Jing Li, Hui Wang, Yikai Wang, Qiongzhi He, Xuefeng Xia, Zhe-Yu Hu, Quchang Ouyang
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Journal of Translational Medicine
Subjects:
Post-menopause HR-positive advanced breast cancer
Fulvestrant
First-line
ctDNA ERBB2 and ESR1 mutation
Poor progress-free survival (PFS)
Online Access:http://link.springer.com/article/10.1186/s12967-018-1734-x

Internet

http://link.springer.com/article/10.1186/s12967-018-1734-x

Similar Items